Akari Therapeutics (AKTX) Stock Price, News & Analysis

Company Overview

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease. In addition, the company is advancing coversin, a small‐protein C5 inhibitor with potential applications in ophthalmology and hematology. These programs leverage Akari’s proprietary platform chemistry to achieve high specificity and subcutaneous dosing convenience.

Headquartered in London, United Kingdom, with research and development operations in the United States, Akari Therapeutics was founded to translate cutting-edge complement science into first-in-class medicines. The company is led by an experienced management team with deep expertise in immunology, drug development and regulatory affairs, and it collaborates with academic institutions and patient organizations to support global clinical studies and future commercialization efforts.

Key Stats

• Today's Range: $9.39 to $10.74
• 50-Day Range: $7.00 to $13.88
• 52-Week Range: $3.02 to $49.60
• Volume: 126,390 shs
• Average Volume: 302,592 shs
• Market Capitalization: $19.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.33
• Consensus Rating: Moderate Buy

Akari Therapeutics Stock Analysis - MarketRank™

Akari Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 265th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Akari Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Akari Therapeutics has a consensus price target of $32.33, representing about 227.3% upside from its current price of $9.88.

Amount of Analyst Coverage

Akari Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Akari Therapeutics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.28% of the float of Akari Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Akari Therapeutics has a short interest ratio ("days to cover") of 0.36, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Akari Therapeutics has recently decreased by 20.03%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akari Therapeutics does not currently pay a dividend.

Dividend Growth

Akari Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Akari Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Akari Therapeutics this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akari Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.20% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

5.06% of the stock of Akari Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 3/31/2020
• Today: 9/17/2026
• Next Earnings (Estimated): 12/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AKTX
• CIK: 1541157
• Web: www.akaritx.com
• Phone: 442080040261
• Fax: 646-843-9352
• Employees: 9
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Akari Therapeutics: $32.33
• High Price Target: $40.00
• Low Price Target: $27.00
• Potential Upside/Downside: +227.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.30 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.45%
• Return on Assets: -74.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $24.75 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 1,950,000
• Free Float: 1,320,000
• Market Cap: $19.27 million
• Optionable: Not Optionable
• Beta: 1.43